Neuropsychiatric symptoms and activities of daily living in Alzheimer’s disease: ALSOVA 5-year follow-up study

Saari, Tapani; Hallikainen, Ilona; Hintsa, Taina; Koivisto, Anne M.

doi:10.1017/s1041610219001571

Cited by 25 publications

(13 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neurodegeneration leads to progressive memory loss (Lane et al, 2018). As the disease progresses, cognitive decline gradually impairs PWAD's communication, attention, basic and complex ADLs with the presence of BPSD (Lane et al, 2018;Saari et al, 2020), resulting in poor QoL (Roehr et al, 2017). Increasing dependency and changes in behavior can also exacerbate caregiver burden (Smith et al, 2018;Vaingankar et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Validation of the Chinese Version of the Relevant Outcome Scale for Alzheimer’s Disease (CROSA)

Zhang

Yang

et al. 2021

Int. Psychogeriatr.

View full text Add to dashboard Cite

Objectives: To examine the psychometric properties of the Chinese version of the Relevant Outcome Scale for Alzheimer’s disease (CROSA) among persons with AD (PWAD) and their caregivers in China. Design: A single-arm, open-label, multi-center study. Setting: Two tertiary general hospitals in Shanghai. Participants: A total of 336 PWAD and their family caregivers. Intervention: The PWAD completed a 12-week treatment with memantine after a baseline assessment. Measurements: The CROSA and the Chinese versions of the Mini-Mental State Examination, the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, the Disability Activity of Dementia, the Neuropsychiatric Inventory Questionnaire, the Zarit Caregiver Burden Interview and the Self-Efficacy Questionnaire for Chinese Family Caregivers. Results: The Cronbach’s alpha for the total scale was 0.900, and the intraclass correlation coefficient and Pearson’s correlation coefficient were 0.910 (P < 0.001) and 0.836 (P < 0.001), respectively. Confirmatory factor analysis revealed the two-factor model to be consistent with the original version. For the known-group validity, the total score of the CROSA classified the PWAD into three stages and three MMSE score groups. Moderate to large correlations with the validated scales confirmed the criteria validity of the CROSA, and the convergent validity was confirmed via testing a hypothesized caregiving model; however, only minimal responsiveness was found among the deterioration group after 12 weeks of treatment with memantine. Conclusions: The reliability and validity of the CROSA was good or acceptable for use in daily clinical settings. Further studies are needed to examine the psychometric properties of the scale.

show abstract

Section: Discussionmentioning

confidence: 99%

Validation of the Chinese Version of the Relevant Outcome Scale for Alzheimer’s Disease (CROSA)

Zhang

Yang

et al. 2021

Int. Psychogeriatr.

View full text Add to dashboard Cite

show abstract

“…In addition, previous studies have suggested that hypercholesterolemia is closely related to cognitive decline [ 27 ]. Clinically, patients with AD are characterized by progressive memory and cognitive decline [ 28 ]. These characteristics are consistent with the changes in the AD model rabbits fed a 2% cholesterol diet.…”

Section: Discussionmentioning

confidence: 99%

GuanXinNing Tablet Attenuates Alzheimer’s Disease via Improving Gut Microbiota, Host Metabolites, and Neuronal Apoptosis in Rabbits

Zhang

Shen

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Based on accumulating evidence, Alzheimer’s disease (AD) is related to hypercholesterolemia, gut microbiota, and host metabolites. GuanXinNing Tablet (GXN) is an oral compound preparation composed of two Chinese herbs, Salvia miltiorrhiza Bge. and Ligusticum chuanxiong Hort., both of which exert neuroprotective effects. Nevertheless, the effect of GXN on AD is unknown. In the present study, we investigated whether GXN alters cholesterol, amyloid-beta (Aβ), gut microbiota, serum metabolites, oxidative stress, neuronal metabolism activities, and apoptosis in an AD model rabbit fed a 2% cholesterol diet. Our results suggested that the GXN treatment significantly reduced cholesterol levels and Aβ deposition and improved memory and behaviors in AD rabbits. The 16S rRNA analysis showed that GXN ameliorated the changes in the gut microbiota, decreased the Firmicutes/Bacteroidetes ratio, and improved the abundances of Akkermansia and dgA-11_gut_group. 1H-NMR metabolomics found that GXN regulated 12 different serum metabolites, such as low-density lipoprotein (LDL), trimethylamine N-oxide (TMAO), and glutamate (Glu). In addition, the 1H-MRS examination showed that GXN remarkably increased N-acetyl aspartate (NAA) and Glu levels while reducing myo-inositol (mI) and choline (Cho) levels in AD rabbits, consequently enhancing neuronal metabolism activities. Furthermore, GXN significantly inhibited oxidative stress and neuronal apoptosis. Taken together, these results indicate that GXN attenuates AD via improving gut microbiota, host metabolites, and neuronal apoptosis.

show abstract

“…Previous studies of the association of NPSs and functional decline have focused on specific symptoms rather than the total symptom load. For example, several studies have found that psychotic symptoms (i.e., delusions and hallucinations) are associated with a more rapid functional decline in AD, 10,15,34 and other studies reported that depressed mood, agitation/aggression, anxiety, and apathy 15,34,35 may be also associated with functional decline. Furthermore, You et al found that sleep nighttime behavior disorders also predicted functional trajectories in AD.…”

Section: Discussionmentioning

confidence: 99%

Neuropsychiatric Symptoms and Functional Decline in Alzheimerʼs Disease and Lewy Body Dementia

Borda

Aarsland

Tovar‐Rios

et al. 2020

J American Geriatrics Society

View full text Add to dashboard Cite

BACKGROUND/OBJECTIVES: Functional status is one of the most important markers of well-being in older adults, but the drivers of functional decline in dementia are not well known. The aim of our work was to study the association of neuropsychiatric symptoms (NPSs) with functional decline over 5 years in newly diagnosed people with Alzheimer´s disease (AD) and Lewy body dementia (LBD). DESIGN: Secondary analysis of the Dementia Study of Western Norway longitudinal cohort study. SETTING: Multicenter study conducted in memory clinics in western Norway. PARTICIPANTS: We included a total of 196 patients newly diagnosed with AD (n = 111) and LBD (n = 85), followed up annually for 5 years. MAIN OUTCOMES AND MEASURES: The outcome was the rapid disability rating scale (items 1-13). Linear mixedeffects models were used for analysis with the total score of the Norwegian Neuropsychiatric Inventory (NPI) as a predictor measured either at baseline or longitudinally, adjusted for potential confounders, including cognition. Effect modification was checked by introducing interactions with NPI score and stratifying by diagnosis. RESULTS: The total NPI score longitudinal course was associated with functional decline in both AD and LBD. At baseline, the total NPI score predicted functional decline in AD. CONCLUSION: NPSs were associated with the rate of functional decline in people with AD and LBD, independent of cognitive impairment. These results highlight the relevance of early detection and intervention of NPSs, which may also reduce functional decline.

show abstract

Neuropsychiatric symptoms and activities of daily living in Alzheimer’s disease: ALSOVA 5-year follow-up study

Cited by 25 publications

References 54 publications

Validation of the Chinese Version of the Relevant Outcome Scale for Alzheimer’s Disease (CROSA)

Validation of the Chinese Version of the Relevant Outcome Scale for Alzheimer’s Disease (CROSA)

GuanXinNing Tablet Attenuates Alzheimer’s Disease via Improving Gut Microbiota, Host Metabolites, and Neuronal Apoptosis in Rabbits

Neuropsychiatric Symptoms and Functional Decline in Alzheimerʼs Disease and Lewy Body Dementia

Contact Info

Product

Resources

About